What is CJC-1295 with DAC?

CJC-1295 with DAC is a synthetic GHRH analog with a Drug Affinity Complex that binds to serum albumin, extending its half-life to 6–8 days. It stimulates sustained growth hormone and IGF-1 release.

What does DAC stand for?

DAC stands for Drug Affinity Complex. It is a maleimido derivative that covalently binds to albumin in the bloodstream, protecting the peptide from degradation and extending its duration of action.

How should CJC-1295 with DAC be stored?

Lyophilized CJC-1295 with DAC should be stored below -18°C, away from light and moisture. Once reconstituted, refrigerate at 2–8°C and use within 7 days.

Has CJC-1295 been tested in clinical trials?

Yes. CJC-1295 reached Phase I/II clinical trials showing significant increases in GH and IGF-1 levels. Development was discontinued, but the peptide remains widely studied in preclinical research.

Is CJC-1295 with DAC FDA approved?

No. CJC-1295 is not approved by the FDA for any medical use. It is prohibited by WADA. All products are sold for research purposes only.

-21%

4X Tested - ISO 17025

99.38% View COA

Growth Peptide

CJC-1295 w/ DAC

Certificate of Analysis

CJC-1295 with DAC is a synthetic 30-amino acid GHRH analog with a drug affinity complex that extends its half-life to 6–8 days, studied for sustained growth hormone and IGF-1 elevation.

Size

Clear

BUNDLE & SAVE

1 Bottle $54.99 MOST POPULAR

2 Bottles $106.14

3+ Bottles $156.72

2-Day Shipping

Free Shipping
over $200

Free shipment
protection

Secure Checkout
256-bit SSL

Description

What is CJC-1295 w/ DAC?

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid analog of growth hormone-releasing hormone (GHRH) developed by ConjuChem Biotechnologies. It features four amino acid substitutions from native GHRH (1-29) that enhance stability against enzymatic degradation.

The DAC component is a maleimido derivative of lysine that forms a covalent bond with serum albumin after injection, dramatically extending the peptide’s half-life from approximately 30 minutes to 6–8 days. This allows for once-weekly dosing in research protocols.

In clinical studies, a single injection of CJC-1295 DAC increased plasma growth hormone levels by 2- to 10-fold for up to 6 days and IGF-1 levels by 1.5- to 3-fold for 9–11 days. The compound reached Phase II clinical trials but was discontinued.

CJC-1295 is not approved by the FDA for any medical use. All products are sold strictly for laboratory and research purposes only.

Research Applications

Areas of Investigation

GH Release

Sustained GH Release

Studied for its ability to maintain elevated growth hormone levels for up to 6 days following a single administration through albumin bioconjugation.

IGF-1

IGF-1 Elevation

Investigated for sustained increases in IGF-1 levels lasting 9–11 days in clinical studies.

Metabolism

Body Composition

Researched for effects on lean mass, fat reduction, and metabolic parameters in growth hormone-related studies.

Bone Health

Bone & Collagen Research

Explored for its potential effects on bone density and collagen synthesis through GH/IGF-1 pathway activation.

Compound Profile

Technical specifications

What is CJC-1295 w/ DAC?

Molecular Profile

Sequence

Y-a-DAIFTQSYRKVLA QLSARKLLDILSRK NH₂*

Molecular Formula

C₁₆₅H₂₇₁N₄₇O₄₆

Molecular Weight

3,647.28 g/mol

Appearance

White lyophilized powder

Form

Lyophilized (freeze-dried)

Handling & Shelf Life Guidelines

Storage & Stability

Storage (Pre-Reconstitution)

Store below -18°C, desiccated, away from light and moisture.

Storage (Post-Reconstitution)

Refrigerate at 2–8°C. For longer storage, aliquot and store below -18°C. Avoid freeze-thaw cycles.

Shelf Life

24 months from date of manufacture when stored as directed

Sensitivity Notes

Sensitive to heat, light, and moisture. Keep sealed until use.

Compliance & Clinical Overview

Regulatory & Research Status

FDA Status

Not approved for human use. Clinical development discontinued.

WADA Classification

Prohibited under class S2 (Peptide Hormones, Growth Factors).

Clinical Trial Status

Published clinical and preclinical studies on sustained GH release, IGF-1 elevation, and body composition effects.

Published Studies

Published clinical and preclinical studies on sustained GH release, IGF-1 elevation, and body composition effects.

Research Disclaimer

For laboratory and research purposes only. Not intended for human consumption.

COA's (Certificate of Analysis)

Third Party Tested by Freedom Diagnostics

99.38%

Purity

Variant

CJC-1295 W/DAC

Lot #

GL-2609-007

Labelled

5mg

Actual

5.16mg

Tested

9/21/2026

View COA

(opens in a new tab)

99.02%